Osteoporosis prevention and treatment

---

• 1.
• O'Neill S, Eisman JA, Glasziou P, et al. The prevention and treatment of osteoporosis [consensus statement]. Med J Aust 1997; 167 (Suppl): S4-S15.
• 2.
• Calcitriol and hypercalcaemia. Aust Adverse Drug React Bull 1997; 16: 2.
• 3.
• Van Staa T, Abenheim L, Cooper C. Upper gastrointestinal adverse events and cyclical etidronate. Am J Med 1997; 103: 462-467.
• 4.
• A gut feeling for alendronate. Aust Adverse Drug React Bull 1999; 18 (3): 11.
• 5.
• Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 1995; 332: 1589-1593.
• 6.
• Nordin BEC. Calcium and osteoporosis. Nutrition 1997; 13: 664-686.
• 7.
• National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: NHMRC, AusInfo 1999.
• 8.
• Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of oestrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 1998; 67: 18-24.
• 9.
• Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. New Engl J Med 1992; 327: 1637-1642.
• 10.
• Lips P, Graafmans WC, Ooms ME, et al. Vitamin D supplementation and fracture incidence in elderly persons. Ann Intern Med 1996; 124: 400-406.
• 11.
• Brock KE, Reid JF, Greenoak GG, Fraser DR, The effect of sunlight on 25-hydroxy vitamin D plasma levels in an elderly Sydney population [abstract]. Australian and New Zealand Bone and Mineral Society Proceedings, 1997, Abstract No. 38.
• 12.
• Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high dose synthetic calcitriol. Ann Intern Med 1990; 113: 649-655.
• 13.
• Ott SM, Chestnut CH. Calcitriol is not effective in postmenopausal osteoporosis. Ann Intern Med 1989; 110: 267-274.
• 14.
• Gallagher JC, Fowler S. Effect of estrogen, calcitriol and a combination of estrogen and calcitriol on bone mineral density and fractures in elderly women [abstract]. J Bone Mineral Res 1999; 14: Abstract no. T364.
• 15.
• Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. New Engl J Med 1992; 326: 357-362.
• 16.
• Ebeling PR, Yeung S, Poon C, et al. Effects of baseline active calcium absorption on bone mineral density responses to calcitriol or calcium treatment in men with idiopathic osteoporosis [abstract]. J Bone Mineral Res 1999; 14: Abstract no. SA419.
• 17.
• Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in postmenopausal osteoporosis. New Engl J Med 1990; 322: 1265-1271.
• 18.
• Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New Engl J Med 1995; 333: 1437-1443.
• 19.
• Black DM, Cummings SR, Karpf D, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.
• 20.
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998; 280: 2077-2082.
• 21.
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomised controlled trial. JAMA 1999; 282: 637-645.
• 22.
• Writing group for the PEPI trial. Effects of hormone therapy on bone mineral density. JAMA 1996; 276: 1389-1396.
• 23.
• Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1-9.
• 24.
• Windeler J, Lange S. Events per person year -- a dubious concept. BMJ 1995; 310: 454-456.
• 25.
• Cauley JA, Seeley, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122: 9-16.
• 26.
• Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605-613.
• 27.
• Cummings SR, Eckert S, Krueger KA. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 281: 2189-2197.
• 28.
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effect of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. New Engl J Med 1997; 337: 1641-1647.
• 29.
• Flicker L, Hopper JL, Larkins RG, et al. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Osteoporosis Int 1997; 7: 29-35.
• 30.
• Arjmandi BH, Birnbaum R, Goyal NV, et al. Bone sparing effect of soy protein in ovarian hormone deficient rats is related to its isoflavone content. Am J Clin Nutr 1998; 68 (Suppl): 1364S-1368S.